2 of 3 products has already been commercialized (RAP just need...

2 of 3 products has already been commercialized (RAP just need to get the ResAppDx's Android version for telehealth completed and create a robust and "quick" benchmark testing which they did for iPhone) so less resource will be need for the acute respiratory diagnosis and OSA, chronic respiratory management which hasn't been yet commercialize use similar technology to ResAppDx so they will be able to extend the process to this so I don't expect much resource will be need for once this product reach the market. But there might be 4 products with massive revenue potential instead of 3 by this time next year......